POZ - CROI 2013 - Conference on Retroviruses and Opportunistic Infections - HIV - AIDS - Hepatitis

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
HIGHLIGHTS
What you need to know
> Blogs > POZ TV > Treatment News > POZ Exclusives > Opinion


Holy Smoke

People with HIV in care smoke at twice the rate of the general population.



Dolutegravir vs. Raltegravir

A Phase III study compares the two integrase inhibitors.



Baby Cured
of HIV?

Data presented at CROI show a child born with HIV and treated with ARVs has been "functionally cured."



Trial Update

Boehringer Ingelhiem's Phase III clinical trial shows 80 percent early success rate for HCV protease inhibitor faldaprevir.


PrEP Progress

Long-acting PrEP injection prevents
anal transmission
of simian HIV.



The Hep C Pipeline

Second-generation antiviral hep C therapies show high cure rates in people who previously failed therapy.



PrEP Trials
for Women

Questions remain after interventions fail to protect from HIV.



Lowering "Bad" Cholesterol

Studies show statin med Livalo is more effective at lowering LDL cholesterol in HIV-positive adults.


Sex and the City

Gay and bisexual men in urban areas are more aware of their HIV status but prevalence holds steady.



Promising Start

A small early trial shows Merck's NNRTI MK-1439 is safe and well tolerated.



Wrapping It Up

Using condoms consistently for anal sex prevents HIV transmission 70% of the time.



Easing Inflammation

ARVs reduce cellular inflammation among elite controllers
of HIV.

NEWSFEED
Coverage from
AIDSmeds & POZ

Each Step of the 'Treatment Cascade' May Not Depend on the Other

Low CD4s, Not Viral Load, Increase Risk of Non-AIDS Diseases for Those Off Treatment

Advances in Gene Therapies That Act Like Fusion Inhibitors

Another Study Finds Gay Black Men at Higher HIV Risk Despite Fewer Partners

Incivek Improves Outcome and Halves Treatment Time for Hep C in HIV-Positive Men

Interferon-Free Hep C Regimen Cures 95% of First-Time Treaters

People With HIV in Care Smoke at Twice the Rate of Those Without

No Change in Rates of Transmitted Drug-Resistant HIV

Gay Urbanites More Aware of Their HIV Status, but Prevalence Holds Steady

Long-Acting PrEP Injection Prevents Anal Simian HIV Transmission

100% Cure Rate for Hep C With Sofosbuvir, Ledipasvir Combo Therapy

Merck’s Non-Nuke MK-1439 Shows Antiviral Activity, Is Safe and Well Tolerated

Simeprevir and Sofosbuvir Achieve High Cure Rates in Hep C Null-Responders

Dolutegravir Appears Superior to Raltegravir Among HIV Salvage Patients

Antiretrovials Reduce Cellular Inflammation Among Elite Controllers of HIV

For People With HIV, Livalo Lowers LDL Better Than Pravachol

Four in Five People With HIV and Hep C on Faldaprevir Achieve Early Treatment Success

Women's PrEP Trial Interventions Fail to Protect From HIV

Used Consistently for Anal Sex, Condoms Prevent 7 in 10 HIV Infections

Baby Born With HIV Is Functionally Cured

> More Newsfeed
FEATURED VIDEO
Footage from the conference
AIDS.gov talks to Dr. Tom Frieden, Director of CDC.
> More POZ TV
JOIN POZ

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Pinterest
PAST CROI COVERAGE
19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, WA
March 5 - 8, 2012


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)
San Francisco, CA
February 16 - 19, 2010


more conference coverage
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.